CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Alzheimers & Dementia is a premier journal published by WILEY that focuses on the latest advancements in understanding, diagnosing, and treating Alzheimer's disease and other dementias. With an ISSN of 1552-5260 and an E-ISSN of 1552-5279, this influential journal boasts a commendable impact factor and ranks in the Q1 category across several disciplines, including *Cellular and Molecular Neuroscience*, *Geriatrics and Gerontology*, and *Neurology (Clinical)*. By publishing cutting-edge research, systematic reviews, and innovative clinical trials, Alzheimers & Dementia aims to bridge the gap between basic neuroscience and clinical practice, offering valuable insights into the etiology, epidemiology, and management of dementia-related disorders. The journal is hosted in the United States and operates under a balanced access model, providing essential resources for researchers, healthcare professionals, and students dedicated to tackling the challenges posed by these neurodegenerative diseases. Available online, it plays a pivotal role in shaping current and future research directions in the vibrant field of dementia studies.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Aging-US is a premier peer-reviewed journal dedicated to advancing the field of aging research and cell biology. Published by IMPACT JOURNALS LLC, this journal serves as a vital resource for researchers and professionals exploring the biological mechanisms of aging and their implications for health and disease. With a commendable impact factor reflected in its 2023 Scopus rankings, where it stands at Rank #10/38 in the category of Aging and Rank #63/285 in Cell Biology, Aging-US exemplifies rigorous scientific excellence. Its open access policy enhances accessibility, fostering a wider dissemination of knowledge in both academic and clinical settings. Spanning from 2009 to 2024, the journal provides a platform for groundbreaking studies and innovative methodologies, ensuring that it remains at the forefront of the dynamic conversations surrounding aging and cellular biology. Engage with Aging-US to contribute to the evolving narratives of longevity and cellular health.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.